Published in Br J Cancer on December 01, 2000
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell (2008) 3.43
TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci U S A (2011) 1.94
Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res (2008) 1.78
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell (2015) 1.77
MYC and Breast Cancer. Genes Cancer (2010) 1.66
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol (2011) 1.65
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer (2006) 1.58
Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res (2011) 1.54
Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A (2004) 1.50
c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol (2007) 1.50
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
MYC and metastasis. Cancer Res (2011) 1.43
Role of autophagy in breast cancer. Autophagy (2007) 1.39
Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol (2006) 1.34
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A (2007) 1.26
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci U S A (2014) 1.25
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene (2009) 1.21
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res (2009) 1.19
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res (2012) 1.18
MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol (2011) 1.15
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res (2011) 1.15
MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol (2006) 1.14
The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis. Proc Natl Acad Sci U S A (2009) 1.10
Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia (2012) 1.08
Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res (2011) 1.06
C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res (2003) 1.04
K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. J Cell Biol (2012) 1.00
Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat (2011) 0.98
Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases--elevated Bmi-1 expression in late breast cancer relapses. Virchows Arch (2011) 0.96
Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat (2009) 0.95
Targeting MYC-Regulated miRNAs to Combat Cancer. Genes Cancer (2010) 0.94
Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS One (2013) 0.94
Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med (Berl) (2010) 0.92
MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer (2014) 0.91
Assessment of palindromes as platforms for DNA amplification in breast cancer. Genome Res (2011) 0.88
C-myc as a predictive marker for chemotherapy in metastatic breast cancer. Clin Exp Med (2011) 0.87
KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Neoplasia (2014) 0.86
Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. Mol Cancer (2004) 0.84
Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer (2007) 0.84
Genetically engineered mice as experimental tools to dissect the critical events in breast cancer. Adv Cancer Res (2014) 0.84
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. Am J Cancer Res (2014) 0.84
Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice. Br J Cancer (2004) 0.83
Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Breast Cancer Res (2008) 0.83
Targeting metabolism in breast cancer: How far we can go? World J Clin Oncol (2016) 0.83
Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Res Treat (2013) 0.82
The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin. PLoS One (2011) 0.81
Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors. World J Gastroenterol (2008) 0.80
Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN. PLoS One (2015) 0.79
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. J Transl Med (2016) 0.79
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. PLoS One (2016) 0.78
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer (2016) 0.77
c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant? Breast Cancer Res (2003) 0.77
Metabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice. Endocr Relat Cancer (2016) 0.76
Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. Oncoimmunology (2015) 0.76
Does radiation-induced c-MYC amplification initiate breast oncogenesis? Mol Cell Oncol (2015) 0.75
Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer. J Mammary Gland Biol Neoplasia (2017) 0.75
Curcumin suppresses the proliferation of gastric cancer cells by downregulating H19. Oncol Lett (2016) 0.75
Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One (2017) 0.75
MYC-Driven Pathways in Breast Cancer Subtypes. Biomolecules (2017) 0.75
Meta-analysis: state-of-the-science. Epidemiol Rev (1992) 8.91
c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol (1999) 8.17
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A (1983) 7.01
Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature (1982) 6.78
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
The molecular genetics of cellular oncogenes. Annu Rev Genet (1984) 5.72
Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell (1986) 3.70
Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (1999) 2.96
Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst (1997) 2.88
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene (1987) 2.67
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A (1986) 2.66
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res (1997) 2.22
Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res (1997) 2.14
Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis (1974) 2.11
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res (1992) 1.59
Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res (1989) 1.58
Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer (1994) 1.55
c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer (1992) 1.46
Proto-oncogene amplification and human breast tumor phenotype. Oncogene (1989) 1.27
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer (1992) 1.26
Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene (1989) 1.25
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res (1989) 1.19
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res (1988) 1.16
Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol (1987) 1.07
In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst (1988) 1.05
Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas. J Cancer Res Clin Oncol (1991) 0.99
Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat (1997) 0.97
Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer (1995) 0.97
Alteration of morphogenesis by the v-myc oncogene in transplants of mammary gland. Oncogene (1988) 0.97
c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer (1989) 0.96
Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer (1996) 0.95
Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer (1990) 0.94
c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer (1992) 0.93
Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res (1993) 0.90
High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers. Int J Cancer (1995) 0.89
Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat (1999) 0.87
A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. Cancer Res (1994) 0.87
Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res (1993) 0.86
Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Res (1994) 0.85
c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res (1995) 0.84
Assessing sequential oncogene amplification in human breast cancer. Cytometry (1995) 0.81
Inverse expression of mdr 1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin d. J Pathol (1996) 0.80
[Drug resistance, oncogenes, and anti-oncogenes in epithelial tumors]. Bull Cancer (1994) 0.80
Analysis of genetic alterations related to the development and progression of breast carcinoma. Jpn J Cancer Res (1993) 0.80
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis. Acta Oncol (1993) 0.78
Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas. Cancer Res (1990) 0.78
Oncogene amplification per se: an independent prognostic factor in human breast cancer. Mol Carcinog (1994) 0.77
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Multicolour spectral karyotyping of mouse chromosomes. Nat Genet (1996) 2.90
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
c-Myc in breast cancer. Endocr Relat Cancer (2000) 2.32
alpha 2-macroglobulin adsorbed to colloidal gold: a new probe in the study of receptor-mediated endocytosis. J Cell Biol (1981) 2.19
Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev (1987) 2.07
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem (1999) 1.93
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res (1998) 1.91
Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of alpha 2-macroglobulin. Proc Natl Acad Sci U S A (1982) 1.76
The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia (1998) 1.75
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol (1987) 1.72
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res (2000) 1.70
Isolation and characterization of a highly enriched preparation of receptosomes (endosomes) from a human cell line. Proc Natl Acad Sci U S A (1983) 1.68
Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem (1999) 1.62
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA (1999) 1.61
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res (1986) 1.58
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol (2001) 1.57
Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem (2001) 1.49
Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy. J Urol (2011) 1.48
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Prelysosomal divergence of transferrin and epidermal growth factor during receptor-mediated endocytosis. Biochemistry (1983) 1.46
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Matrix metalloproteinase inhibitors. Invest New Drugs (1997) 1.43
Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (1986) 1.41
Serendipity in diagnostic imaging: magnetic resonance imaging of the breast. J Natl Cancer Inst (1998) 1.38
Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem (1997) 1.36
Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst (1992) 1.36
The effect of hospital volume on cancer control after radical prostatectomy. J Urol (2005) 1.36
Receptor-mediated endocytosis in cultured fibroblasts: cryptic coated pits and the formation of receptosomes. J Histochem Cytochem (1981) 1.35
Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene (2000) 1.29
A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer (1999) 1.26
Estrogen receptor in adult male rat liver. Endocrinology (1978) 1.26
Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis (1994) 1.24
New approaches to proteomic analysis of breast cancer. Proteomics (2001) 1.23
Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A (1987) 1.22
Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology (1986) 1.19
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Binding and internalization of 125I-alpha 2-macroglobulin by cultured fibroblasts. J Biol Chem (1981) 1.17
Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog (1992) 1.17
Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res (1993) 1.14
Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol (1992) 1.13
Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res (1993) 1.12
Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res (1993) 1.12
Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology (1995) 1.11
The EGF receptor system as a target for antitumor therapy. Cancer Invest (1991) 1.11
8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat (1986) 1.11
Adherence to colorectal cancer screening in an HMO population. Prev Med (1990) 1.10
Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ (1995) 1.10
Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat (1998) 1.09
Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat Res (1988) 1.08
Induction of ductal morphogenesis and lobular hyperplasia by amphiregulin in the mouse mammary gland. Cell Growth Differ (1996) 1.08
Potential biomarker for early risk assessment of prostate cancer. Prostate (2006) 1.08
A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol (1988) 1.08
A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem (1992) 1.08
Irradiation-related ischemic heart disease. J Clin Oncol (1990) 1.07
Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene (1998) 1.07
Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia (1999) 1.06
ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res (1989) 1.06
Trihalomethanes in drinking water and human colorectal cancer. J Natl Cancer Inst (1984) 1.06
Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem (1986) 1.06
Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res (1996) 1.05
Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells. Cancer Res (1989) 1.05
EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat (1994) 1.03
Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol (1989) 1.03
Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells. Clin Exp Metastasis (1995) 1.01
The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res (1993) 1.01
Internalization of alpha 2 macroglobulin in receptosomes. Studies with monovalent electron microscopic markers. Exp Cell Res (1981) 0.99
Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Exp Cell Res (1999) 0.98
Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Urology (2001) 0.98
Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res (1991) 0.98
Age and survival from squamous cell carcinoma of the oral tongue. Head Neck (2001) 0.98
Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat (1997) 0.97
Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. Cancer Treat Res (1992) 0.97
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J Med Chem (2001) 0.97
Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene (2000) 0.97
Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J Cell Biochem (1987) 0.96
Differential alteration of stem and other cell populations in ducts and lobules of TGFalpha and c-Myc transgenic mouse mammary epithelium. Tissue Cell (2005) 0.95
Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. Bioorg Med Chem Lett (2001) 0.95
Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem (1991) 0.95
The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo. Mol Endocrinol (1989) 0.95
Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res (1988) 0.94
Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology (1990) 0.94
c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells. Br J Cancer (2003) 0.94
Transforming growth factor alpha production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Mol Endocrinol (1989) 0.94
Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Horm Res (1989) 0.93
Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol Endocrinol (1988) 0.93
The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res (1996) 0.93
The process of malignant progression in human breast cancer. Ann Oncol (1990) 0.93
Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene (1996) 0.92
Ultrastructure of the putative stem cell niche in rat mammary epithelium. Tissue Cell (2003) 0.91
Tissue culture conditions determine the effects of estrogen and growth factors on the anchorage independent growth of human breast cancer cell lines. J Steroid Biochem Mol Biol (1991) 0.91
Receptor-mediated endocytosis of alpha 2-macroglobulin: inhibition by ionophores and stimulation by Na+ and HCO3(-). Ann N Y Acad Sci (1982) 0.91
Reversible and irreversible inhibitors of clustering of alpha 2M in clathrin-coated pits on the surface of fibroblasts. Exp Cell Res (1982) 0.90